" class="no-js "lang="en-US"> Genentech - Medtech Alert
Thursday, September 04, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Genentech | Pharmtech Focus

Genentech

About Genentech

Genentech

About Genentech

We’re passionate about finding solutions for people facing the world’s most difficult-to-treat conditions. That is why we use cutting-edge science to create and deliver innovative medicines around the globe. To us, science is personal.

Making a difference in the lives of millions starts when you make a change in yours. If you’d like to join our team, view our openings at gene.com/careers.

Our patient resource center is dedicated to getting patients and caregivers to the right resources. You can reach them at 1 (877) GENENTECH (436-3683)
Monday-Friday, 6am-5pm PST or patientinfo@gene.com.

Related Story

Diseases

 Jemincare Announces Exclusive License Agreement with Genentech to Develop and Commercialize Novel Oral Androgen Receptor Degrader | Pharmtech Focus

Jemincare Announces Exclusive License Agreement with Genentech to Develop and Commercialize Novel Oral Androgen Receptor Degrader

August 18 2022

Jemincare, a leading pharmaceutical company from China, announced today that it and its wholly owned subsidiary […]

Industry News

 PRISM BioLab

PRISM BioLab Enters Multi-Project Drug Discovery Collaboration with Roche and Genentech

January 5 2022

PRISM BioLab, a Japan based biotechnology company with a proprietary peptide mimetic small molecule drug discovery […]

Industry News

 Bicycle Therapeutics Announces Expansion of Genentech Immuno-Oncology Collaboration | Pharmtech Focus

Bicycle Therapeutics Announces Expansion of Genentech Immuno-Oncology Collaboration

October 27 2021

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics […]